BLADDER TISSUE BANK
膀胱组织库
基本信息
- 批准号:8167199
- 负责人:
- 金额:$ 6.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-03-01 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdjuvant TherapyBiologicalBiological MarkersBiologyBladderBladder TissueCXC ChemokinesCoinComputer Retrieval of Information on Scientific Projects DatabaseFailureFundingGrantImmunityImmunotherapyInstitutionInterferonsInvadedLamina PropriaMalignant neoplasm of urinary bladderMediatingMusclePatientsProtocols documentationRecurrenceRenal Cell CarcinomaResearchResearch PersonnelResourcesRoleSourceStagingTherapeutic InterventionTissue BankingTissue BanksUnited States National Institutes of Healthangiogenesisbaseimprovedsuccesstumor
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
There has been controversy related to the management of non-muscle invasive bladder cancer, which invades the lamina propria (pT1). This stage of bladder cancer has a significant propensity for recurrence and progression. We need to further understand the role of immunotherapy and/or whether this form of therapy should be optimized in order to improve therapeutic intervention of early stage bladder cancer, especially in those patients with recurrence of their tumor in the context of adjuvant BCG therapy. On the basis of the ability of interferon-inducible CXC chemokines to promote Th1 immunity and inhibit angiogenesis, we have coined the term, "immunoangiostasis" for their potential biological role in promoting tumor regression. Recently, we have identified the importance of the biology of immunoangiostasis in mediating tumor regression related to renal cell carcinoma. In this proposal, we hypothesize that the biology of immunoangiostasis is critical to the full success of adjuvant immunotherapy with BCG in patients with non-muscle invasive bladder cancer. Moreover, we postulated that in patients who fail to respond to this type of adjuvant therapy,, failure is due to their inability to manifest a full immunoangiostatic effect to their tumor. This latter concept would also suggest that there may be immunoangiostatic mechanisms that could be further optimized in order to fully mediate immunoangiostasis in these tumors. The protocol submitted for review will be used to determine whether the expression of interferon-inducible CXC chemokines in patients with non-muscle invasive bladder can be used as a biomarker to predict those patients that will respond vs. patients that will fail to respond to immunotherapy.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
关于侵犯固有层(PT1)的非肌肉浸润性膀胱癌的治疗一直存在争议。这个阶段的膀胱癌有很大的复发和进展的倾向。我们需要进一步了解免疫治疗的作用和/或是否应该优化这种治疗形式,以改善对早期膀胱癌的治疗干预,特别是在辅助卡介苗治疗的情况下,对肿瘤复发的患者。基于干扰素诱导的CXC趋化因子促进Th1免疫和抑制血管生成的能力,我们创造了“免疫血管抑制”这一术语,因为它们在促进肿瘤消退方面具有潜在的生物学作用。最近,我们已经确认了免疫血管抑制生物学在介导与肾癌相关的肿瘤消退中的重要性。在这项建议中,我们假设免疫血管稳定的生物学对于卡介苗辅助免疫治疗在非肌肉浸润性膀胱癌患者中的完全成功至关重要。此外,我们推测,在对这种辅助治疗无效的患者中,失败是由于他们无法对肿瘤表现出完全的免疫血管抑制效应。后一个概念还表明,可能存在免疫血管抑制机制,可以进一步优化,以便在这些肿瘤中充分介导免疫血管稳定。提交审查的方案将用于确定干扰素诱导的CXC趋化因子在非肌肉侵袭性膀胱患者中的表达是否可以用作预测免疫治疗有效患者与无效患者的生物标志物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAN THEODORESCU其他文献
DAN THEODORESCU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAN THEODORESCU', 18)}}的其他基金
The Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression
Y 染色体在膀胱肿瘤发生、生长和进展中的作用
- 批准号:
10629079 - 财政年份:2023
- 资助金额:
$ 6.28万 - 项目类别:
Understanding the AGL metastasis suppressor for therapeutic gain
了解 AGL 转移抑制因子的治疗效果
- 批准号:
9223676 - 财政年份:2010
- 资助金额:
$ 6.28万 - 项目类别:
Understanding the AGL metastasis suppressor for therapeutic gain
了解 AGL 转移抑制因子的治疗效果
- 批准号:
9030867 - 财政年份:2010
- 资助金额:
$ 6.28万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 6.28万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 6.28万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 6.28万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 6.28万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 6.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 6.28万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 6.28万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 6.28万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 6.28万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 6.28万 - 项目类别:
Operating Grants